Previous 10 | Next 10 |
RedHill Biopharma (RDHL) announces that it has entered into an underwriting agreement with H.C. Wainwright under which the underwriter has agreed to purchase on a firm commitment basis 1.25M American Depositary Shares ((ADSs)) of the company, at a price of $8/ADS, with gross proceeds expected...
RedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary Shares PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , March 1, 2021 /PRNewswire/ -- RedHill Biopharma Ltd . (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biop...
RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S. Following review of data from the U.S. Phase 2 study by the FDA, RedHill plans to expand the global Phase 2/3 study of orally-administered opaganib for severe COVID-19 to the U....
RedHill Biopharma (RDHL) inks agreements with Cosmo Pharmaceuticals to manufacture two key products; Movantik, and RHB-204.Movantik is prescribed oral peripherally acting mu-opioid receptor antagonist to treat opioid-induced constipation in adult patients with chronic non-cancer pain.RHB-204 ...
RedHill Biopharma Strengthens Partnership with Cosmo Pharmaceuticals with Manufacturing Agreements for Movantik and RHB-204 The agreements secure high-quality manufacturing capacity of Movantik® for opioid-induced constipation and RHB-204, currently in a Phase 3 study for p...
RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107 - The U.S. Phase 2/3 study with once-daily, orally-administered RHB-107 (upamostat) evaluates treatment of patients with symptomatic COVID-19 who do not require hospitalizati...
RedHill Biopharma to Present at SVB Leerink Global Healthcare and BIO CEO & Investor Conferences RedHill Biopharma to Present at SVB Leerink Global Healthcare and BIO CEO & Investor Conferences PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , Feb. 9...
The Independent Data Safety Monitoring Board ((DSMB)) has unanimously recommended to continue the study of RedHill Biopharma's (RDHL) Phase 2/3 study of opaganib in patients with severe COVID-19, following a pre-scheduled futility review.Preclinical data have demonstrated ...
RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib Following interim review of unblinded safety and efficacy data, independent DSMB unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib f...
RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals New agreement further expands manufacturing capacity for orally-administered opaganib following positive top-line data from its Phase 2 COVID-19 study, progress with the ong...
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd. Company Name:
RDHL Stock Symbol:
NASDAQ Market:
Redhill Biopharma Ltd. Website:
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 22, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biophar...
RedHill Biopharma Terminates License Agreement for Aemcolo® PR Newswire TEL-AVIV, Israel and RALEIGH, NC , July 9, 2024 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today ...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...